Results from Phase III study show tirzepatide is superior to semaglutide in Type 2 diabetes

In the SURPASS-2 trial, the dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist was associated with HbA1c reductions of 2.46% (15mg) and 2.09% (5mg) compared to 1.86% with semaglutide. Bodyweight was reduced by 13.1%, 8.5% and 6.7%, respectively

Biospace Inc.